Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021

Shots:

• The P-I/II KRYSTAL–1 study evaluates adagrasib (600mg, bid) as monothx. and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation following prior systemic therapy
• The therapy showed the clinical activity and broad disease control. As of May 25 & July 9, 2021, 80% of patients received adagrasib mononthx. & 90% with combination; median follow up of 8.9 & 7mos.; response rate (22% & 43%) including unconfirmed PR (1 & 2); DCR (87% & 100%) respectively, m-DoR (4.2mos.) & m-PFS (5.6mos.) in monothx. therapy
• Additionally, the therapy was well-tolerated with a manageable safety profile, grade 3/4 TRAEs (30% in monothx. & 16% in combination)

Click here to­ read full press release/ article | Ref: Mirati | Image: Trading View